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ABSTRACT
DNA-PK is an enzyme that is required for proper DNA-repair and is thought to confer 
radio-resistance in cancer cells. As a consequence, it is a high-profile validated target for 
new pharmaceutical development. However, no FDA-approved DNA-PK inhibitors have 
emerged, despite many years of drug discovery and lead optimization. This is largely 
because existing DNA-PK inhibitors suffer from poor pharmacokinetics. They are not well 
absorbed and/or are unstable, with a short plasma half-life. Here, we identified the first 
FDA-approved DNA-PK inhibitor by “chemical proteomics”. In an effort to understand 
how doxycycline targets cancer stem-like cells (CSCs), we serendipitously discovered 
that doxycycline reduces DNA-PK protein expression by nearly 15-fold (> 90%). In 
accordance with these observations, we show that doxycycline functionally radio-
sensitizes breast CSCs, by up to 4.5-fold. Moreover, we demonstrate that DNA-PK is 
highly over-expressed in both MCF7- and T47D-derived mammospheres. Interestingly, 
genetic or pharmacological inhibition of DNA-PK in MCF7 cells is sufficient to functionally 
block mammosphere formation. Thus, it appears that active DNA-repair is required 
for the clonal expansion of CSCs. Mechanistically, doxycycline treatment dramatically 
reduced the oxidative mitochondrial capacity and the glycolytic activity of cancer cells, 
consistent with previous studies linking DNA-PK expression to the proper maintenance 
of mitochondrial DNA integrity and copy number. Using a luciferase-based assay, we 
observed that doxycycline treatment quantitatively reduces the anti-oxidant response 
(NRF1/2) and effectively blocks signaling along multiple independent pathways 
normally associated with stem cells, including STAT1/3, Sonic Hedgehog (Shh), Notch, 
WNT and TGF-beta signaling. In conclusion, we propose that the efficacy of doxycycline 
as a DNA-PK inhibitor should be tested in Phase-II clinical trials, in combination with 
radio-therapy. Doxycycline has excellent pharmacokinetics, with nearly 100% oral 
absorption and a long serum half-life (18–22 hours), at a standard dose of 200-mg 
per day. In further support of this idea, we show that doxycycline effectively inhibits 
the mammosphere-forming activity of primary breast cancer samples, derived from 
metastatic disease sites (pleural effusions or ascites fluid). Our results also have 
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possible implications for the radio-therapy of brain tumors and/or brain metastases, as 
doxycycline is known to effectively cross the blood-brain barrier. Further studies will be 
needed to determine if other tetracycline family members also confer radio-sensitivity.
INTRODUCTION
Recently, we employed a label-free quantitative 
proteomics approach to discover new therapeutic targets 
in tumor-initiating cells (TICs) and/or cancer stem-like 
cells (CSCs) [1]. Briefly, ER-positive breast cancer lines 
were cultured under suspension conditions, allowing for 
the formation of mammospheres (a.k.a., tumor-spheres). 
Then, we compared the proteome of these tumor-spheres 
directly to attached monolayer cells grown in parallel. 
Using this approach, we identified several functional groups 
of proteins that were specifically up-regulated in tumor-
spheres, relative to epithelial monolayers. More specifically, 
mitochondrial proteins were dramatically over-expressed, 
including key enzymes related to beta-oxidation and ketone 
metabolism, as well as proteins involved in mitochondrial 
biogenesis, and specific protein inhibitors of mitophagy [1]. 
Interestingly, our approach revealed > 60 mitochondrial-
related target proteins that were significantly over-expressed 
in tumor-spheres. These mitochondrial proteins were also 
transcriptionally over-expressed in human breast cancer 
samples, highlighting their potential clinical importance. As 
such, we believe that increased mitochondrial biogenesis 
could provide a new mechanism for the accumulation of 
mitochondrial mass in CSCs.
We also utilized a pharmacological approach to 
functionally validate the importance of mitochondrial fuels, 
by employing a specific MCT1/2 inhibitor, which prevents 
the uptake of two mitochondrial fuels, ketone bodies and 
L-lactate. Notably, inhibition of MCT function significantly 
inhibited tumor-sphere formation in both ER-positive and 
ER-negative breast cancer cell lines, with an IC-50 of 
~1–2 μM [1]. Oligomycin A, an inhibitor of Complex V, the 
mitochondrial ATP-synthase, showed very similar inhibitory 
activity. Taken together, these results provide suggestive 
evidence that the proliferative expansion of CSCs strictly 
depends upon oxidative mitochondrial metabolism [1]. 
These findings could have future clinical implications for 
eradicating CSCs, to minimize or prevent tumor recurrence, 
metastasis and drug resistance. Of course, this would depend 
on the clinical development of new non-toxic mitochondrial 
inhibitors that are safe for the treatment of breast cancer 
patients, which could require 10–15 years of intensive 
pharmaceutical development and investment.
In summary, using this unbiased proteomic approach, 
we identified a conserved dependence on mitochondrial 
biogenesis for the clonal expansion and survival of CSCs. 
Interestingly, it is well-known that certain FDA-approved 
antibiotics inhibit mitochondrial biogenesis as a mild, 
clinically manageably, side-effect [2–6]. Thus, we recently 
proposed that these antibiotics could be re-purposed as a 
relatively non-toxic approach to target CSCs. This approach 
would dramatically accelerate the potential use of 
mitochondrial inhibitors in cancer patients [7].
Using this strategy, we experimentally identified 5 
different classes of mitochondrially-targeted antibiotics that 
successfully targeted CSCs [7]. Importantly, these FDA-
approved drugs inhibited the growth of CSCs in 12 different 
cancer cell lines, across 8 different tumor types (breast, 
DCIS, ovarian, prostate, lung, pancreatic, melanoma, and 
glioblastoma (brain)). The use of generic antibiotics for 
cancer therapy could significantly reduce the costs of patient 
care, making treatment more accessible.
Doxycycline is one of the most promising drugs that 
emerged from these studies [7]. Since its FDA-approval in 
1967, it has been successfully used as a broad-spectrum 
antibiotic for nearly 50 years, without any major side-
effects. Currently, acne patients use doxycycline safely for 
chronic therapy, for up to 6 months at a time, at a standard 
dose of 200-mg per day [8, 9].
Mechanistically, in mammalian cells, doxycycline 
functions as an inhibitor of mitochondrial biogenesis, by 
binding to the small subunit of the mitochondrial ribosome 
[2–4, 10, 11]. Doxycycline targets the mitochondrial 
ribosome, as mitochondria evolved from bacteria over 
millions of years of evolution [12, 13]. Therefore, bacterial 
ribosomes and mitochondrial ribosomes show many 
conserved properties and protein homologies. Recent clinical 
trials with doxycycline (intended to target cancer-associated 
infections, but not cancer cells) have already shown positive 
therapeutic effects in lymphoma patients, although their 
ability to eradicate CSCs was not yet appreciated [14–15].
Here, to better understand the mechanism(s) of 
action of doxycycline on cancer cell metabolism, we 
used an unbiased proteomics approach to identify which 
proteins are effectively down-regulated by doxycycline. 
This led to identification of doxycycline as the first 
FDA-approved inhibitor of DNA-PK, which has broad 
clinical implications for the use of doxycycline as a radio-
sensitizer, to overcome radio-resistance in CSCs.
Throughout this paper, we have used the term cancer 
stem-like cells (CSCs) or tumor-initiating cells (TICs). For 
a very insightful discussion of the emerging terminology 
surrounding the definition of CSCs or TICs, please see the 
following review (16).
RESULTS
Doxycycline inhibits mammosphere formation, 
as assessed using primary breast cancer samples 
derived from metastatic disease sites
Previously, we established that the antibiotic 
doxycycline effectively inhibits tumor-sphere formation 
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in 12 different cell lines, across eight different cancer 
types, including breast cancer. More specifically, both 
ER-positive (MCF7/T47D) and ER-negative (MDA-
MB-231) cell lines were all sensitive to doxycycline 
treatment [7]. Interestingly, all three of these cell lines 
were originally derived from the pleural effusions of 
breast cancer patients, with metastatic disease. Thus, 
we next tested if primary breast cancer samples derived 
from metastatic disease sites were also sensitive to 
doxycycline.
Importantly, Figure 1 shows that that doxycycline 
dose-dependently inhibits mammosphere formation in 
primary patient samples derived from metastatic disease 
sites (either pleural effusions or ascites fluid). Moreover, 
doxycycline appeared to work equally well in samples 
derived from either ER-positive or ER-negative patients 
(N = 4 patients in total) (See also Supplemental Figure 1). 
As such, we obtained quantitatively similar results with 
both well-established cell lines and primary breast cancer 
samples.
Figure 1: Doxycycline inhibits mammosphere formation, as assessed using primary breast cancer samples derived 
from metastatic disease sites. Upper panel: ER-positive (N = 2 patients); Middle panel: ER-negative (N = 2 patients); Lower panel: 
ER-positive and negative samples combined (N = 4 patients). Note that doxycycline dose-dependently inhibits mammosphere formation in 
primary patient’s samples derived from metastatic disease sites (either pleural effusions or ascites). Doxycycline appears to work equally 
well in samples derived from either ER-positive or ER-negative patients. All experiments were performed in triplicate.
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These results are consistent with previous studies 
showing that doxycycline dramatically inhibits the in vivo 
growth of metastatic lesions (bone and soft tissue) in a 
mouse model of breast cancer, by up to 60-to-80% [17].
Doxycycline pre-treatment reduces the 
mammosphere forming capacity of MCF7 
monolayer cells
To better understand how doxycycline inhibits the 
growth of CSCs, we used an unbiased proteomic approach 
to identify its potential molecular targets. For this purpose, 
we established conditions under which doxycycline 
selectively inhibits the proliferation of CSCs, but not 
“bulk” cancer cells.
First, MCF7 cells were pre-treated with doxycycline 
(50 μM) as monolayers for 7- days and then re-plated for 
the mammosphere assay, in the absence of doxycycline. 
Figure 2 shows that pre-treatment with doxycycline, 
under these conditions, is sufficient to significantly reduce 
mammosphere forming capacity. However, this 7-day 
treatment also significantly reduced proliferation in MCF7 
cell monolayers to a similar extent, but did not affect the 
viability of the remaining cells.
Therefore, we next shortened the pre-treatment 
period to 3-days. Importantly, under these new conditions, 
doxycycline (50 μM) reduced the mammosphere forming 
capacity of MCF7 cells by ~ 50%, without affecting the 
proliferation of the bulk monolayer cells (Figure 3). Thus, 
doxycycline can be used to selectively reduce “stemness” 
in MCF7 monolayers.
Identification of the molecular targets of 
doxycycline, using unbiased label-free 
proteomics analysis: DNA-PK emerges as 
a new target
Next, to begin to understand the molecular basis 
of this selectively, we used these culture conditions 
to perform unbiased proteomics analysis on MCF7 
monolayers (treated with doxycycline for 3-days). The 
results of this analysis are summarized in Table 1. Only 
proteins reduced by ≥ 1.5-fold (p < 0.05) were considered 
in the analysis. Importantly, Table 1 clearly highlights 
that doxycycline pre-treatment of MCF7 cell monolayers 
significantly reduced the expression of many key protein 
targets functionally associated with mitochondrial 
metabolism, glycolysis, the EMT, protein synthesis and 
the DNA damage response, as well as inflammation and 
protein degradation, in human breast cancer cells.
Interestingly, using this approach, we identified 
DNA-PK as the protein target that was most dramatically 
down-regulated by doxycycline, by nearly 15-fold 
(> 90% reduction) (Table 1). DNA-PK (also known 
as PRKDC) is the catalytic subunit of the DNA-dependent 
protein kinase involved in DNA-repair. DNA-PK is 
required for DNA-repair using the mechanism of NHEJ 
(non-homologous end joining) [18] [19]. DNA-PK 
also functions to maintain the integrity and copy number 
of mt-DNA, so there is a clear link with mitochondrial 
metabolic function, as well [20].
Consistent with our current findings, we also 
observed that DNA-PK is significantly over-expressed 
in both MCF7 and T47D mammospheres (Table 2). 
Remarkably, DNA-PK is infinitely upregulated in MCF7 
mammospheres and nearly 15-fold increased in T47D 
mammospheres, relative to monolayer cultures.
Clinical relevance of “doxycycline reduced 
targets” in human breast cancers
To determine the potential clinical relevance of our 
proteomic findings, we next assessed whether the protein 
targets reduced by doxycycline were transcriptionally 
upregulated in human breast cancer cells in vivo.
For this purpose, we employed a published clinical 
data set of N = 28 breast cancer patients in which their 
tumor samples were subjected to laser-capture micro-
dissection, to physically separate epithelial cancer 
cells from their adjacent tumor stroma [21]. Table 3 
presents a summary of these findings. Importantly, most 
of the protein targets reduced by doxycycline were 
transcriptionally upregulated in human breast cancer cells 
in tumors excised from patients.
In light of these findings, the new “doxycycline 
reduced targets” that we identified may be particularly 
relevant, for improving both the diagnosis and treatment 
of human breast cancers.
Validation of DNA-PK as a therapeutic 
target in CSCs
To validate the potential relevance of DNA-PK 
for maintaining the growth of CSCs, we next used an 
sh-RNA-approach. Briefly, MCF7 cells were transduced 
with lentiviral vectors harboring either control sh-RNA 
or sh-RNA species targeting the expression of DNA-PK. 
Figure 4A illustrates that MCF7 cells harboring the DNA-
PK sh-RNA show a 50% reduction in mammosphere 
forming capacity, as predicted. Loss of DNA-PK 
expression was indeed confirmed by immunoblot analysis, 
using specific antibody probes (Figure 4A).
Validation was also performed using a well-
established DNA-PK inhibitor, namely KU-57788 
[NU-7441] [22, 23]. Figure 4B directly shows that 
KU-57788 [NU-7441] dose-dependently inhibits 
MCF7 mammosphere formations, with an IC-50 between 
100 nM and 1 μM.
Thus, DNA-PK activity appears to be required 
for the efficient clonal expansion and anchorage-
independent growth of CSCs, as observed using the 
mammosphere assay.
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Doxycycline pre-treatment sensitizes CSCs to 
radiation treatment
Since DNA-PK has been previously implicated in 
the radio-resistance of cancer cells [24, 25] and we show 
here that doxycycline functionally reduces the expression 
of DNA-PK, we would predict that doxycycline treatment 
should radio-sensitize CSCs.
Figure 2: Doxycycline pre-treatment of MCF7 
monolayers inhibits mammosphere formation: Effects 
at 7-days. MCF7 cells were pre-treated with doxycycline 
(50 μM) as monolayers for 7-days and then re-plated for the 
mammsphere assay, in the absence of doxycycline. Note that pre-
treatment with doxycycline, under these conditions, is sufficient 
to significantly reduce mammosphere forming capacity. 
However, this 7-day treatment also reduced proliferation in 
MCF7 cell monolayers to a similar extent, but did not affect the 
viability of the remaining cells. Each data point in this figure is 
the average of 9 replicates.
To test this hypothesis directly, MCF7 cell 
monolayers were pre-treated with doxycycline (50 μM) 
for 3-days and then irradiated. After radiation treatment, 
monolayers were trypsinized and re-plated to evaluate 
mammosphere growth over a 5-day period. Figure 5 shows 
that radiation treatment significantly increases the growth 
of CSCs by up to 1.45-fold, as expected. In contrast, 
doxycycline pre-treatment increased the sensitivity of 
CSCs to radiation by up to 4.5-fold. However, under these 
conditions, doxycycline pre-treatment (with or without 
radiation) had little or no effect on the proliferation or 
viability of the “bulk” cancer cells (Figure 6A, 6B).
Figure 3: Doxycycline pre-treatment of MCF7 
monolayers inhibits mammosphere formation: Effects 
at 3-days. MCF7 cells were pre-treated with doxycycline 
(50 μM) as monolayers for 3-days and then re-plated for 
the mammosphere assay, in the absence of doxycycline. 
Under these conditions, doxycycline (50 μM) reduced the 
mammosphere forming capacity of MCF7 cells by ~ 50%, 
without affecting the proliferation of the bulk monolayer 
cells As such, doxycycline can be used to selectively reduce 
“stemness” in MCF7 monolayers. Each data point in this figure 
is the average of 9 replicates.
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Thus, doxycycline pre-treatment functionally 
sensitizes CSCs to radiation, as predicted based on its 
ability to reduce DNA-PK expression.
Validation of the metabolic phenotype induced 
by doxycycline pre-treatment
Based on our proteomics analysis presented in 
Table 1, both the levels of key mitochondrial proteins 
and glycolytic enzymes were significantly reduced by 
doxycycline pre-treatment. Thus, these results suggest 
that doxycycline should reduce overall metabolic 
activity in cancer cells.
To test this hypothesis further, we next examined 
the metabolic profile of MCF7 cell monolayers 
pre-treated with doxycycline (50 μM) for 2-days. 
Interestingly, Figure 7 shows that the rates of both 
oxidative mitochondrial metabolism and glycolysis were 
dramatically reduced by doxycycline pre-treatment, as 
measured using the Seahorse XFe96 analyzer to measure 
metabolic flux. This resulted in significant reductions in 
respiration (basal and maximal), as well as reduced ATP 
levels (Figure 8). Finally, as seen in Figure 9, MCF7 
cancer cells were shifted from a highly energetic to a 
metabolically quiescent state.
Doxycycline reduces the anoikis-resistance of 
MCF7 cells, prior to mammosphere formation
Anoikis is a specific type of programmed cell 
death (apoptosis) that is induced in certain cell types, 
under anchorage-independent growth conditions [26, 27]. 
Interestingly, epithelial CSCs show anoikis-resistance, and 
are able to undergo mammosphere formation under these 
anchorage-independent conditions [28].
Next, to determine the possible effects on anoikis-
resistance, MCF7 cells were pre-treated with doxycycline 
(at 25 or 50 μM) as monolayers for 2-days and then re-
plated on low-attachment plates, for either the anoikis 
assay or the mammosphere assay, in the absence of 
doxycycline.
Importantly, Figure 10 shows that doxycycline 
pre-treatment dose-dependently reduced the number of 
live cells remaining after 10 hours of seeding on low-
attachment plates. Under these conditions, doxycycline 
pre-treatment also dose-dependently reduced the 
mammosphere forming capacity of MCF7 cells, by 
up to ~ 50%. Thus, doxycycline may exert its inhibitory 
effects on mammosphere formation, in part, by effectively 
reducing anoikis-resistance, during the initial time spent 
under low-attachment conditions.
Doxycycline simultaneously inhibits the 
functional activity of multiple stem-cell 
associated signal transduction pathways
To better understand which signaling pathways 
are affected by doxycycline treatment, we used a panel 
of eight MCF7-GFP cell lines engineered to express 
different luciferase-based transcriptional reporters. 
The functional activation state of these reporters was 
then normalized by GFP expression, to account for cell 
number.
Interestingly, Figure 11 directly shows that 
doxycycline treatment of MCF7 monolayer cultures 
inhibits both the anti-oxidant response (NRF1/2) and 
STAT1/3 signaling, especially at 72 and 96 hours. 
Similarly, Figure 12 illustrates that doxycycline also 
dampens signaling along four other stem-cell associated 
pathways, including Sonic Hedgehog, Notch, WNT and 
TGF-beta signaling, again most prominently at 72 and 
96 hours. Interestingly, in several cases, a bi-phasic 
response was noted, with activation of signaling at 
24 hours, and progressive inhibition from 48-to-96 hours.
These results directly support our observation that 
doxycycline potently inhibits mammosphere formation, 
by blocking the clonal expansion of CSCs and reduces 
anoikis-resistance. Indeed, it has been reported that most 
of these signaling pathways such as Notch, Hedgehog, 
WNT, TGFβ, STAT3 or NRF1/2 are able to confer anoikis-
resistance, and inhibition of these pathways sensitizes 
CSCs to anoikis.
Table 1: MCF7 cell proteins down-regulated in response to doxycycline treatment of monolayer 
cultures (3-days at 50 μM)
Symbol Gene Description Down-regulation
(fold-change)
ANOVA
Mitochondrial-related Proteins
PRKDC DNA-dependent protein kinase catalytic subunit (maintains mt-DNA integrity & copy number) 14.71 0.02
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial 5.29 1.55E-06
(Continued )
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(Continued )
Symbol Gene Description Down-regulation
(fold-change)
ANOVA
MDH2 Malate dehydrogenase 2, mitochondrial 3.08 4.01E-06
ECI1 Enoyl-CoA delta isomerase 1, mitochondrial 2.95  0.018
VDAC1 Voltage-dependent anion-selective channel protein 1 2.71 9.65E-05
HSPD1 60 kDa heat shock protein, mitochondrial 2.24  0.004
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial 1.94 0.02
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 1.91 0.002
SDHA Succinate dehydrogenase complex subunit A 1.88 0.0001
ALDH18A1 Delta-1-pyrroline-5-carboxylate synthase, mitochondrial 1.88 0.006
COX6A Cytochrome c oxidase subunit 6A, mitochondrial 1.84 0.008
FASN Fatty acid synthase 1.83 0.02
LRPPRC Leucine-rich PPR-motif containing (inhibitor of mitophagy) 1.72 0.002
ORP150 150 kDa oxygen-regulated protein 1.70 0.02
NDUFA4 NADH dehydrogenase (Ubiquinone) 1 alpha-subcomplex, 4 1.68 0.0007
COX5B Cytochrome c oxidase subunit 5B, mitochondrial 1.66 0.0008
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b 1.57 0.02
Glycolytic Enzymes
GPI Glucose-6-phosphate isomerase 3.82 8.06E-05
LDHA L-lactate dehydrogenase A 2.26 0.02
TPI1 Triosephosphate isomerase 1 2.25  0.004
ENO1 Enolase 1 1.71 0.005
ALDOA Fructose-bisphosphate aldolase A 1.57 0.007
PGK1 Phosphoglycerate kinase 1 1.57 0.037
LDHB L-lactate dehydrogenase B 1.53 0.03
PKM1/2 Pyruvate kinase 1.45 0.03
EMT-markers/Muscle-related proteins (cytoskeletal)/Extracellular Matrix/Angiogenesis
SMOC2 SPARC-related modular calcium-binding protein 2 7.01 5.17E-06
MYO18B Unconventional myosin-XVIIIb 6.48 0.0002
TUBB1 Tubulin beta-1 chain 3.72 3.09E-05
ADAM22 A disintegrin and metalloproteinase domain 22 3.49 8.96E-05
PLEC1 Plectin 1, intermediate filament binding protein 500kDa 2.86 0.0001
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 2.37 0.035
ACTBL2 Beta-actin-like protein 2 2.28 0.008
CTNNB1 Catenin (Cadherin-associated protein), beta 1, 88kDa 2.07 0.02
CFL2 Cofilin-2 2.11 0.0004
CFL1 Cofilin-1 (Non-muscle), isoform 2.01 0.04
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(Continued )
Symbol Gene Description Down-regulation
(fold-change)
ANOVA
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 1.91 0.04
SRRM2 Serine/arginine repetitive matrix protein 2 1.85 0.006
AMOT Angiomotin 1.79 0.0005
MYH15 Myosin-15 1.76 0.0003
MYH10 Myosin-10 1.73 0.02
TUBA4B Putative tubulin-like protein alpha-4B 1.67 0.003
USMG5 Up-regulated during skeletal muscle growth protein 5 1.58 0.02
KIF5C Kinesin heavy chain isoform 5C 1.58 0.009
TUBA1A Tubulin alpha-1A chain 1.50 0.01
Protein Synthesis and Transport, Glycosylation and Glycosaminoglycan Synthesis (GAGs)
EIF3C Eukaryotic translation initiation factor 3 subunit C 7.24 0.0002
VCP Valosin-containing protein 4.95 7.38E-06
RPL9 60S ribosomal protein L9 4.94 6.46E-05
SARS Seryl (serine)-tRNA synthetase 4.85 0.0002
PMM2 Phosphomannomutase 2 4.45 1.43E-05
SURF4 Surfeit locus protein 4 3.53 5.63E-05
EEF1G Elongation factor 1-gamma 3.18 7.42E-05
EIF3A Eukaryotic translation initiation factor 3 subunit A 3.04 0.0007
RPB4 60S ribosomal protein L4 2.81 0.02
EIF3G Eukaryotic translation initiation factor 3 subunit G 2.77 7.33E-06
RAB2 RAB2, member RAS oncogene family 2.59 0.03
COPG1 Coatomer subunit gamma-1 2.34 0.003
HSP90AB1 Heat shock protein 90kDa alpha (Cytosolic), class B member 1 2.29 0.02
UGDH UDP-glucose 6-dehydrogenase 2.28 0.03
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 2.21 0.004
RRBP1 p180/ribosome receptor 2.19 0.04
AP1G1 AP-1 complex subunit gamma-1 1.98 0.002
RPS18 40S ribosomal protein S18 1.97 0.007
RAB21 RAB21, member RAS oncogene family 1.88 0.02
RPL15 60S ribosomal protein L15 1.82 0.026
RPL7 60S ribosomal protein L7 1.75 0.03
STIP1 Stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) 1.72 0.003
P4HB Protein disulfide-isomerase 1.69 0.02
RPS16 40S ribosomal protein S16 1.59 0.015
RPS2 40S ribosomal protein S2 1.57 0.008
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Symbol Gene Description Down-regulation
(fold-change)
ANOVA
RPL35 60S ribosomal protein L35 1.55 0.02
SEC22B Vesicle-trafficking protein SEC22b 1.50 0.037
DNA-binding, Nuclear-related, and Cell Cycle Control
PRKDC DNA-dependent protein kinase catalytic subunit (non-homologous 
end joining (NHEJ))
14.71 0.02
XRN2 5’-3’ exoribonuclease 2 5.53 0.0006
NAP1L4 Nucleosome assembly protein 1-like 4 4.46 0.002
ESF1 Nucleolar Pre-RRNA Processing Protein, Homolog 4.30 2.00E-08
NASP Nuclear autoantigenic sperm protein 4.12 0.009
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 3.85 9.30E-05
FUBP1 Far upstream element-binding protein 1 3.21 1.44E-05
POLD3 DNA polymerase delta subunit 3 3.09 0.0007
RPA1 Replication protein A 70 kDa DNA-binding subunit 2.80 0.02
CHD4 Chromodomain-helicase-DNA-binding protein 4 2.62 5.68E-05
CTPS1 CTP synthase 2.37 0.0003
LMNA Prelamin-A/C 2.22 0.01
CEP110 Centrosomal protein 110kDa 2.02 0.03
MCM7 MCM7 minichromosome maintenance deficient 7 1.96 0.03
NAP1L1 Nucleosome assembly protein 1-like 1 1.86 0.015
HDAC1 Histone deacetylase 1 1.71 0.045
SP100 Nuclear autoantigen Sp-100 1.64 0.03
DHX9 ATP-dependent RNA helicase A 1.47 0.02
Inflammation/Immune Function
LTA4H Leukotriene A(4) hydrolase 3.52 1.16E-06
CCT4 T-complex protein 1 subunit delta 2.13 0.0003
CCT2 T-complex protein 1 subunit beta 1.53 0.04
Protein Degradation
UBR4 E3 ubiquitin-protein ligase UBR4 3.47 0.002
STUB1 E3 ubiquitin-protein ligase CHIP 2.55 0.01
PSMC3 Proteasome (prosome, macropain) 26S subunit, ATPase 3 1.79 0.04
PSMB4 Proteasome subunit beta type-4 1.72 0.003
PSMD2 Proteasome 26S non-ATPase subunit 2 1.58 0.04
UBE1
Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature 
sensitivity complementing) 1.55 0.003
UBE2V1 Ubiquitin-conjugating enzyme E2 variant 1 1.47 0.03
USP14 Ubiquitin carboxyl-terminal hydrolase 14 1.47 0.007
Note that doxycycline targets mitochondrial metabolism, glycolysis, the EMT, protein synthesis and the DNA damage 
response, as well as inflammation and protein degradation, in human breast cancer cells.
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Table 3: Doxycycline-targets normally up-regulated in human breast cancer cells in vivo
Symbol Gene Description Up-regulation 
(fold-change)
P-value
Mitochondrial-related Proteins
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b 5.39 7.83E-07
COX5B Cytochrome c oxidase subunit 5B, mitochondrial 5.03 2.86E-06
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 4.84 5.73E-06
COX6A Cytochrome c oxidase subunit 6A, mitochondrial 4.46 2.07E-05
LRPPRC Leucine-rich PPR-motif containing (inhibitor of mitophagy) 4.34 3.15E-05
NDUFA4 NADH dehydrogenase (Ubiquinone) 1 alpha-subcomplex, 4 4.25 4.29E-05
MDH2 Malate dehydrogenase 2, mitochondrial 4.18 5.32E-05
HSPD1 60 kDa heat shock protein, mitochondrial 3.42 5.93E-04
DECR1 2,4-dienoyl CoA reductase 1, mitochondrial 3.38 6.86E-04
VDAC1 Voltage-dependent anion-selective channel protein 1 2.64 5.35E-03
PRKDC DNA-dependent protein kinase catalytic subunit (maintains mt-DNA integrity & copy number) 2.14 0.02
Glycolytic Enzymes
TPI1 Triosephosphate isomerase 1 4.21 4.88E-05
ALDOA Fructose-bisphosphate aldolase A 3.60 3.45E-04
GPI Glucose-6-phosphate isomerase 3.36 7.28E-04
PKM2 Pyruvate kinase 3.26 9.79E-04
PGK1 Phosphoglycerate kinase 1 2.46 8.66E-03
LDHA L-lactate dehydrogenase A 2.42 9.42E-03
ENO1 Enolase 1 1.96 0.03
EMT-markers/Muscle-related proteins (cytoskeletal)
CFL1 Cofilin-1 (Non-muscle), isoform 2.39 0.01
TUBB1 Tubulin beta-1 chain 2.32 0.01
TUBA1A Tubulin alpha-1A chain 2.17 0.02
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 2.07 0.02
CTNNB1 Catenin (Cadherin-associated protein), beta 1, 88kDa 2.05 0.02
MYH10 Myosin-10 1.82 0.037
KIF5C Kinesin heavy chain isoform 5C 1.82 0.037
Protein Synthesis and Transport
RPL7 60S ribosomal protein L7 5.21 1.53E-06
Table 2: DNA-PK is highly up-regulated in both MCF7 and T47D mammospheres, as compared 
with monolayer cultures
Cell Line Symbol Gene Description Up-regulation 
(fold-change)
ANOVA
MCF7 PRKDC DNA-dependent protein kinase, catalytic subunit Infinity 1.13E-10
T47D PRKDC DNA-dependent protein kinase, catalytic subunit 14.85 2.60E-05
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Symbol Gene Description Up-regulation 
(fold-change)
P-value
RPS18 40S ribosomal protein S18 4.96 3.71E-06
HSP90AB1 Heat shock protein 90kDa alpha (Cytosolic), class B member 1 4.94 4.03E-06
RPS2 40S ribosomal protein S2 4.77 7.21E-06
RPL15 60S ribosomal protein L15 4.60 1.28E-05
EIF3C Eukaryotic translation initiation factor 3 subunit C 4.48 1.94E-05
RPL35 60S ribosomal protein L35 4.10 7.05E-05
RAB2 RAB2, member RAS oncogene family 3.73 2.29E-04
RPL9 60S ribosomal protein L9 3.71 2.49E-04
EEF1G Elongation factor 1-gamma 3.71 2.44E-04
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 3.16 1.30E-03
RPS16 40S ribosomal protein S16 3.05 1.77E-03
RPL4 60S ribosomal protein L4 3.05 1.79E-03
SEC22B Vesicle-trafficking protein SEC22b 3.04 1.81E-03
EIF3A Eukaryotic translation initiation factor 3 subunit A 2.51 7.57E-03
SARS Seryl (serine)-tRNA synthetase 2.15 0.02
P4HB Protein disulfide-isomerase 2.15 0.02
EIF3G Eukaryotic translation initiation factor 3 subunit G 1.92 0.03
DNA-binding, Nuclear-related, and Cell cycle control
HDAC1 Histone deacetylase 1 4.15 6.02E-05
NAP1L4 Nucleosome assembly protein 1-like 4 4.07 7.61E-05
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 4.03 8.90E-05
RPA1 Replication protein A 70 kDa DNA-binding subunit 2.52 7.30E-03
MCM7 MCM7 minichromosome maintenance deficient 7 2.23 0.015
NAP1L1 Nucleosome assembly protein 1-like 1 2.19 0.017
PRKDC DNA-dependent protein kinase catalytic subunit (non-homologous end 
joining (NHEJ))
2.14 0.02
CTPS1 CTP synthase 2.09 0.02
CHD4 Chromodomain-helicase-DNA-binding protein 4 1.87 0.034
Inflammation/Immune Function
CCT4 T-complex protein 1 subunit delta 3.25 1.00E-03
LTA4H Leukotriene A(4) hydrolase 2.94 2.40E-03
CCT2 T-complex protein 1 subunit beta 2.85 3.06E-03
Protein Degradation
PSMB4 Proteasome subunit beta type-4 4.16 5.70E-05
PSMD2 Proteasome 26S non-ATPase subunit 2 3.31 8.29E-04
USP14 Ubiquitin carboxyl-terminal hydrolase 14 3.23 1.05E-03
STUB1 E3 ubiquitin-protein ligase CHIP 1.95 0.03
UBR4 E3 ubiquitin-protein ligase UBR4 1.77 0.04
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DISCUSSION
Recently, we proposed that FDA-approved 
antibiotics that adversely effect mitochondria could be used 
to effectively target the cancer stem cell population, by 
inhibiting mitochondrial biogenesis in tumor-initiating 
cells (TICs) [7]. One of these promising antibiotics is 
doxycycline, a member of the tetracycline class, with 
excellent pharmacokinetics.
To better understand how doxycycline exerts its 
therapeutic effects, here we used a chemical proteomics 
approach [29, 30] to more effectively interrogate the 
target-phenotype relationship. Our results directly 
show that doxycycline treatment significantly 
reduced the expression of many key protein targets 
functionally associated with mitochondrial metabolism, 
glycolysis, the EMT, protein synthesis and the DNA 
damage response, as well as inflammation and protein 
degradation, in human breast cancer cells. We further 
validated that doxycycline suppresses both oxidative 
mitochondrial metabolism and glycolysis, using 
metabolic flux analysis. Doxycycline also inhibited 
signal transduction along multiple stem-cell associated 
communication pathways, namely Sonic Hedgehog, 
Notch, WNT and TGF-beta signaling.
Interestingly, using this approach, we also identified 
DNA-PK as the protein target that was most dramatically 
down-regulated by doxycycline, by nearly 15-fold (> 90% 
reduction) (Figure 13). DNA-PK is required for effective 
cellular DNA-repair and also maintains the integrity and 
Figure 4: DNA-PK is required for mammosphere formation in MCF7 cells. A. Genetic approach. MCF7 cells were transduced 
with lentiviral vectors harboring either control sh-RNA or sh-RNA species targeting the expression of DNA-PK. Note that MCF7 cells 
harboring the DNA-PK sh-RNA show a 50% reduction in mammosphere forming capacity, as predicted. B. Pharmacological approach. Note 
that the well-established DNA-PK inhibitor, namely KU-57788 [NU-7441], dose-dependently inhibits MCF7 mammosphere formations, 
with an IC-50 between 100 nM and 1 μM. As such, DNA-PK activity is required for the efficient clonal expansion and anchorage-
independent growth of CSCs, as observed using the mammosphere assay. Each data point in this figure is the average of 9 replicates.
A
B
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Figure 5: Doxycycline pre-treatment sensitizes cancer stem cells to radiation treatment. MCF7 cell monolayers 
were pre-treated with doxycycline (50 μM) for 3-days and then irradiated. After radiation treatment, monolayers were trypsinized and 
re-plated to evaluate mammosphere growth over a 5-day period. Note that radiation treatment significantly increases the growth of 
CSCs by up to 1.45-fold, as expected. In contrast, doxycycline pre-treatment increased the sensitivity of CSCs to radiation by up to 4.5-fold. 
In conclusion, doxycycline pre-treatment functionally sensitizes CSCs to radiation, as predicted based on its ability to reduce DNA-PK 
expression. Each data point in this experiment is the average of 18 replicates.
Figure 6: Doxycycline pre-treatment does not inhibit the growth and viability of MCF7 cell monolayers. As in Figure 4, 
MCF7 cell monolayers were pre-treated with doxycycline (50 μM) for 3-days and then irradiated. However, note that under these conditions 
doxycycline pre-treatment (with or without radiation), had little or no effect on the proliferation or viability of the “bulk” cancer cells. Each 
data point in this experiment is the average of 18 replicates.
A
B
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copy number of mitochondrial DNA [20, 31, 32]. DNA-
PK is thought to confer radiation resistance in cancer 
cells [33–35], but has never been previously implicated in 
the growth of CSCs.
Additional validation experiments, using 
both genetic (DNA-PK sh-RNA) and pharmacological 
(DNA-PK inhibitor: NU-7441) approaches directly 
showed that DNA-PK expression or activity is required 
for MCF7 cells to efficiently form mammospheres. This 
is the first demonstration that DNA-PK is required for the 
clonal expansion and survival of CSCs. Most importantly, 
however, pre-treatment of MCF7 cell monolayers with 
doxycycline was sufficient to increase the sensitivity of 
CSCs to radiation treatment, by up to 4.5-fold.
Unfortunately, no FDA-approved DNA-PK inhibitors 
have emerged, despite many years of drug discovery 
and lead optimization. This is largely because existing 
DNA-PK inhibitors suffer from poor pharmacokinetics. 
They are not well absorbed and/or are unstable, with a 
short plasma half-life [36–38]. In contrast, doxycycline 
Figure 7: Doxycycline treatment reduces the rates 
of both oxidative mitochondrial metabolism and 
glycolysis. We examined the metabolic profile of MCF7 cell 
monolayers pre-treated with doxycycline (50 μM) for 2-days. 
Note that the rates of both oxidative mitochondrial metabolism 
and glycolysis were significantly reduced by doxycycline pre-
treatment, as measured using the Seahorse XFe96 analyzer to 
measure metabolic flux.
Figure 8: Doxycycline quantitatively reduces 
respiration (basal and maximal) and ATP levels. We 
examined the metabolic profile of MCF7 cell monolayers pre-
treated with doxycycline (50 μM) for 2-days, using the Seahorse 
XFe96 analyzer to measure metabolic flux. Note that significant 
reductions in respiration (basal and maximal), as well as reduced 
ATP levels, were observed experimentally. Each data point in 
this figure is the average of 9 replicates.
Oncotarget14019www.impactjournals.com/oncotarget
has excellent pharmacokinetics, with nearly 100% oral 
absorption and a long serum half-life (18–22 hours), at a 
standard dose of 200-mg per day [39, 40].
Thus, we propose that the efficacy of doxycycline as 
a DNA-PK inhibitor should be tested in Phase-II clinical 
trials, in combination with radio-therapy. In further 
support of this idea, we show that doxycycline effectively 
inhibits the mammosphere-forming activity of primary 
breast cancer samples, derived from metastatic disease 
sites (pleural effusions or ascites fluid).
MATERIALS AND METHODS
Materials
Breast cancer cell lines (MCF7 and T47D) were 
purchased from the ATCC. Gibco-brand cell culture 
media (DMEM and DMEM/F12) was purchased from Life 
Technologies. Doxycycline was purchased from Sigma-
Aldrich. Sh-RNA lentiviral particles targeting DNA-PK 
(sc-35200-V) were obtained commercially from Santa 
Cruz Biotech (USA), along with appropriate sh-RNA 
control particles (sc-108080). Antibodies directed against 
DNA-PK (MS-423-P0) for immunoblot analysis were 
obtained from Thermo Scientific. KU-57788 [NU-7441] 
was obtained from Selleckchem.
Description of primary tumor samples from 
metastatic disease sites
Ethical approval was granted by the Central 
Office for Research Ethics Committee (study numbers: 05/
Q1402/25 and 05/Q1403/159) and patients gave 
written informed consent. Metastatic fluid samples 
were obtained from 4 patients undergoing palliative 
drainage of symptomatic ascites or pleural effusions 
at The Christie Hospital, Manchester, UK. Estrogen, 
progesterone, and HER2 receptor status of the primary 
Figure 9: Doxycycline shifts MCF7 cancer cells from a 
highly energetic to a metabolically quiescent state. We 
examined the metabolic profile of MCF7 cell monolayers pre-
treated with doxycycline (50 μM) for 2-days, using the Seahorse 
XFe96 analyzer to measure metabolic flux. Note that MCF7 
cancer cells were shifted towards a metabolically quiescent 
state. Each data point in this figure is the average of 9 replicates.
Figure 10: Doxycycline reduces the anoikis-resistance 
of MCF7 cells, prior to mammosphere formation. MCF7 
cells were pre-treated with doxycycline (at 25 or 50 μM) as 
monolayers for 2-days and then re-plated on low-attachment 
plates, for the anoikis assay or the mammosphere assay, in the 
absence of doxycycline. A. Anoikis Assay. Note that doxycycline 
pre-treatment dose-dependently reduced the number of live cells 
remaining after 10 hours of seeding on low-attachment plates. 
B. Mammosphere formation. Note that, under these conditions, 
doxycycline pre-treatment dose-dependently reduced the 
mammosphere forming capacity of MCF7 cells, by up to ~ 50%. 
Each data point in this figure is the average of 9 replicates.
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tumors were reported by the Department of Pathology at 
The Christie, according to established criteria [41].
Isolation of breast cancer epithelial cells
Metastatic breast cancer cells were harvested as 
previously described, with minor modifications [42]. 
Invasive breast cancer tissue (1–2 cm3) was collected, 
dissected into 1–2 mm3 cubes, and digested in media 
comprised of Dulbecco’s Modified Eagle’s Media 
(DMEM), 15 mM HEPES, and 10% collagenase/
hyaluronidase (Stem Cell Technologies) (supplemented 
with Pen-Strep) at 37oC for 16 hours. Digested tissue 
was filtered sequentially through 100, 70, and 40 μm 
sieves. Red blood cells were removed using Lymphoprep 
(Axis-Shield), and leukocytes were removed with CD45-
negative magnetic sorting according to the manufacturer’s 
instructions (Miltenyi Biotech).
Figure 11: Doxycycline treatment of MCF7 monolayers inhibits the anti-oxidant response (NRF1/2) and STAT1/3 
signaling. Note that doxycycline is especially effective at 72 and 96 hours. Each data point in this figure is the average of at least 8 
replicates.
Figure 12: Doxycycline dampens signaling along four major stem-cell associated pathways in MCF7 cells, namely 
Sonic Hedgehog, Notch, WNT and TGF-beta signaling. Note that the functional effects of doxycycline were most prominent at 
72 and 96 hours. In several cases, a bi-phasic response was noted, with activation of signaling at 24 hours, and progressive inhibition from 
48-to-96 hours. Each data point in this figure is the average of at least 8 replicates.
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Figure 13: Doxycycline targets mitochondrial 
biogenesis and DNA-repair, ultimately converging 
on ATP production and energy metabolism in cancer 
cells. DNA-PK activity is normally required for repairing mt-
DNA and maintaining mt-DNA copy number. Mitochondrial 
biogenesis is dependent on mitochondrial protein synthesis, 
which is carried out, in part, by mitochondrial ribosomes, 
which share significant homology with bacterial ribosomes. 
Doxycycline targets both mitochondrial ribosomes and DNA-
PK, thereby reducing ATP levels, as observed experimentally.
Pre-treatment of monolayers with doxycycline, 
with and without radiation treatment
MCF7 cells were plated in normal medium (DMEM, 
10% FCS, L-glutamine, supplemented with Pen-Strep) 
for 24-hr. Cells were then treated, initially for 7 days 
with doxycycline, with media changed every 3 days. For 
subsequent experiments, cells were treated for 72-hr. For 
radiation experiments, monolayer cells pre-treated with 
doxycycline, were exposed to increasing levels of radiation, 
and the cells collected by trypsinization and centrifugation. 
To quantitatively determine cell growth, the number 
of cells remaining after treatment was counted using an 
automatic cell counter (Biorad), compared to untreated 
cells and expressed as fold-change. To assess cell viability, 
cells were incubated for 1 minute with Trypan Blue 
(Sigma, #T8145) using a 1:1 ratio. The number of Trypan 
Blue positive cells (non-viable) was measured using an 
automatic cell counter (Biorad) and compared to untreated 
controls. Cells were also plated into mammosphere cultures 
to assess stem cell-like activity with no further drug 
treatment. All experiments were performed in triplicate and 
repeated at least three times independently.
Irradiation of MCF7 monolayers using a cell 
x-ray unit
MCF7 cells were pre-treated at a monolayer 
for 3 days, with either doxycycline (50 μM) or with 
vehicle-alone, and then were irradiated with 0–10 Gy 
at room temperature, using an X-ray unit, at a dose-
rate of 1.37 Gy/min. More specifically, irradiation was 
performed using a free-standing 320 kV x-ray system 
(Gulmay Medical Ltd, now Xstrahl Ltd, Camberley, UK). 
The machine was operated at 300 kV, 10 mA with the 
addition of a 0.75 mm Cu filter to give a beam quality 
with half-value layer (HVL) of 2.3 mm Cu. Samples were 
positioned at a distance of 500 mm from the x-ray focus 
and a backscatter block was utilised to ensure good dose 
uniformity. The dose rate to samples was determined to be 
1.37 Gy/min [43]. This dose rate was checked regularly 
using the IPEM 2005 protocol and equipment whose 
calibration was traceable to UK national standards.
Lentiviral transduction
Lentiviral particles harboring human DNA-PK 
sh-RNA (#sc-35200-V, Santa Cruz) or control shRNA 
lentiviral Particles (#sc-108080, Santa Cruz), were 
used to stably transduce MCF7 cells, according to the 
manufacturer’s protocol (in the presence of 5 μg/ml 
polybrene). Twenty-four hours post-infection, media 
containing the virus was removed and replaced with 
standard media. Cells were then selected with 2 μg/ml 
puromycin, for up to 10 days.
Immunoblot analysis
MCF7 cells were seeded in 10 cm dishes for 72 hrs. 
Then, cells were lysed in RIPA buffer (Sigma), containing 
proteinase inhibitors (Roche) and kept at 4°C for 
30 minutes. Lysates were collected by centrifugation for 
10 minutes at 10,000 × g, and protein concentration were 
determined using the BCA protein assay kit (Pierce). 
Samples were diluted into SDS-PAGE sample buffer 
and were boiled for 5 minutes before being separated by 
SDS-PAGE, using a 4–15% gradient Mini-PROTEAN 
TGX Gel (Biorad). Samples were then transferred 
onto a nitrocellulose membrane (Biorad), blocked in 
5% milk in TBS-Tween 20 (Sigma) and probed with 
antibodies directed against DNA-PK (ThermoScientific, 
#MS-423-P0) and β-actin (Santa Cruz Biotechnology, 
#sc-1616), using a secondary antibody at a dilution of 
1 to 5000. Bound antibodies were detected using the 
Supersignal West Pico Chemiluminiscent substrate 
(ThermoScientific).
Mammosphere culture
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) to create a 
single cell suspension [44]. Cells were plated at a density 
of 500 cells/cm2 in mammosphere medium (DMEM-F12/
B27/20 ng/ml EGF/PenStrep) in non-adherent conditions, 
in culture dishes coated with (2-hydroxyethylmethacrylate) 
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(poly-HEMA, Sigma, #P3932). Cells were grown for 
5 days and maintained in a humidified incubator at 37°C 
at an atmospheric pressure in 5% (v/v) carbon dioxide/air. 
After 5 days for culture, spheres > 50 μm were counted 
using an eye piece graticule, and the percentage of cells 
plated which formed spheres was calculated and is 
referred to as percentage mammosphere formation, and 
was normalized to one (1 = 100% MSF). For proteomic 
analysis, mammospheres were collected by centrifugation 
at 800 rpm for 10 minutes and compared to monolayer 
cells grown for 5 days.
Label-free quantitative proteomics analysis
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS [45]. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLCnano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
replicates were analyzed for each sample type (N = 5). 
Statistical analyses were performed using ANOVA and 
only fold-changes in proteins with a p-value less than 0.05 
were considered significant.
Data mining
To firmly establish the clinical relevance of our 
results from the quantitative proteomics analysis of 
mammosheres, we re-analyzed the transcriptional profiles 
of epithelial breast cancer cells and adjacent tumor 
stromal cells that were physically separated by laser-
capture microdissection (from N = 28 human breast cancer 
patients) [21].
Seahorse XFe96 metabolic flux analysis
Extracellular acidification rates (ECAR) and real-
time oxygen consumption rates (OCR) for MCF7 and 
MCF7 treated with doxycycline were determined using the 
Seahorse Extracellular Flux (XFe96) analyzer (Seahorse 
Bioscience, MA, USA). MCF7 cells were maintained in 
DMEM supplemented with 10% FBS (fetal bovine serum), 
2 mM GlutaMAX, and 1% Pen-Strep. We seeded 7,000 
cells per well into XFe96 well cell culture plates and they 
were incubated overnight at 37°C in a 5% CO
2
 humidified 
atmosphere. After 24 h, the cells were treated with DOX 
(25 μM and 50 μM) for 48 h in XFe96 cell culture plates. 
After 48 h of incubation in DMEM media, MCF-7 cells 
were washed in XF assay media (or for OCR measurement, 
XF assay media supplemented with 10 mM glucose, 1 mM 
Pyruvate, 2 mM L-glutamine and adjusted at 7.4 pH), 
which were pre-warmed to 37°C. MCF7 cells were then 
maintained in 175 μL/well of XF assay media at 37°C, in a 
non-CO2 incubator for 1 h. During the cell incubation time, 
we loaded 25 μL of 80 mM glucose, 9 μM oligomycin, 
1M 2-deoxyglucose (for ECAR measurement) and 
10 μM oligomycin, 9 μM FCCP, 10 μM rotenone, 10 μM 
antimycin A (for OCR measurement), in XF assay media 
into the injection ports in the XFe96 sensor cartridge. 
Measurements were normalized by protein content. 
Data set was analyzed by XFe96 software and GraphPad 
Prism software, using one-way ANOVA and Student’s 
t-test calculations. All experiments were performed in 
quintuplicate, three times independently, such that each data 
point represents the average of 15 replicates.
Anoikis assay
Following doxycycline treatment, the CSC population 
was enriched by seeding on low-attachment plates. Under 
these conditions, the non-CSCs undergo anoikis (a form of 
apoptosis induced by a lack of cell-substrate attachment) 
and CSCs are believed to survive. The surviving “CSC 
fraction” was analyzed by FACS analysis. Briefly, 1 × 104 
MCF7 cells were treated with doxycycline (25 μM and 
50 μM) for 48 h in 6-well plates, grown as a monolayer. 
Then, the monolayer cells were trypsinized and seeded 
in low-attachment plates in mammosphere media. After 
10 h under low-attachment conditions, MCF7 cells were 
spun down and incubated with LIVE/DEAD dye (Fixable 
Dead Violet reactive dye; Invitrogen) for 20 minutes to 
distinguish between the live and dead populations of cells 
(cell viability), during anoikis. Samples were then analyzed 
by FACS (Fortessa, BD Bioscence) and the data were 
analysed using FlowJo software.
Monitoring cell signal transduction pathways
The Cignal Lenti luciferase reporter assay was used to 
monitor the activity of several signaling pathways in MCF7-
GFP cells, essentially as previously described [46, 47]. 
Briefly, viral particles diluted 1:10 in complete media 
containing polybrene (sc-134220, Santa Cruz) were added 
to the cells. Puromycin treatment (P9620, Sigma) was added 
48 h later in order to stably select infected cells. Luciferase 
assays (E1501, Promega) were performed according to 
manufacturer’s instructions. Approximately 6 × 103 MCF7 
cells were seeded in black-walled 96 well plates. When cells 
were attached, drug treatments were added for 24, 48, 72 
and 96 h. Four replicates were used for each condition. After 
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treatment, the luciferase assay was performed according to 
manufacturer’s instructions and light signal was acquired 
in the Xenogen VivoVision IVIS Lumina. Results were 
normalized by GFP fluorescence.
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